These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9315428)

  • 1. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
    Glasziou PP; Simes RJ; Hall J; Donaldson C
    Control Clin Trials; 1997 Oct; 18(5):464-76. PubMed ID: 9315428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
    Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
    Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
    Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
    Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
    Szucs TD; Berger K; März W; Schäfer JR
    Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
    Glasziou PP; Eckermann SD; Mulray SE; Simes RJ; Martin AJ; Kirby AC; Hall JP; Caleo S; White HD; Tonkin AM
    Med J Aust; 2002 Oct; 177(8):428-34. PubMed ID: 12381252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
    Tonkin AM; Colquhoun D; Emberson J; Hague W; Keech A; Lane G; MacMahon S; Shaw J; Simes RJ; Thompson PL; White HD; Hunt D
    Lancet; 2000 Dec; 356(9245):1871-5. PubMed ID: 11130382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
    McConnachie A; Walker A; Robertson M; Marchbank L; Peacock J; Packard CJ; Cobbe SM; Ford I
    Eur Heart J; 2014 Feb; 35(5):290-8. PubMed ID: 23839541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
    Muls E; Van Ganse E; Closon MC
    Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.
    Avorn J; Benner J; Ford I; Ganz DA; Gaw A; Glynn RJ; Jackson J; Lagaay AM; Schneeweiss S; Walley T; Wang PS;
    Control Clin Trials; 2002 Dec; 23(6):757-73. PubMed ID: 12505250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
    Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
    Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
    Ashraf T; Hay JW; Pitt B; Wittels E; Crouse J; Davidson M; Furberg CD; Radican L
    Am J Cardiol; 1996 Aug; 78(4):409-14. PubMed ID: 8752184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients].
    Berger K; Klose G; Szucs TD
    Med Klin (Munich); 1997 Jun; 92(6):363-9. PubMed ID: 9297070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris.
    Am J Cardiol; 1995 Sep; 76(7):474-9. PubMed ID: 7653447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
    Keech A; Colquhoun D; Best J; Kirby A; Simes RJ; Hunt D; Hague W; Beller E; Arulchelvam M; Baker J; Tonkin A;
    Diabetes Care; 2003 Oct; 26(10):2713-21. PubMed ID: 14514569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
    Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
    BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
    Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.